Ambenonium
Cholinesterase Inhibitor — NERVOUS SYSTEM
Also known as: ambenonium chloride, ambestigmin chloride, mytelase, mytelase chloride
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Ambenonium is an ofm drug in the Cholinesterase Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 1956. Its mechanism of action is classified as Cholinesterase Inhibitors. DrugCentral lists 3 molecular targets, including ACHE, Ache and ACHE. Recorded indications include Myasthenia gravis.
- Approval status: ofm (first approved 1956 by the FDA).
- Drug class: Cholinesterase Inhibitor.
- Mechanism of action: Cholinesterase Inhibitors.
- Molecular targets: ACHE, Ache and ACHE (3 listed in DrugCentral).
- Indications: Myasthenia gravis.
- ATC code: N07AA30 (Anticholinesterases).
- Molecular formula: C28H42Cl2N4O2; molecular weight 537.57 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Myasthenia gravis
Contraindications (4)
- Asthma
- Gastrointestinal obstruction
- Parkinsonism
- Urinary tract obstruction
Mechanism & targets
| Mechanism of action (MoA) | Cholinesterase Inhibitors |
|---|---|
| Established pharmacologic class | Cholinesterase Inhibitor |
Molecular targets (3)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Acetylcholinesterase | ACHE | unknown | IC50 9.92 |
| Acetylcholinesterase | Ache | unknown | Kd 4.34 |
| Acetylcholinesterase | ACHE | inhibitor | — |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1956-05-01 | FDA | — | SANOFI AVENTIS US |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
N07AA30 | NERVOUS SYSTEM › OTHER NERVOUS SYSTEM DRUGS › PARASYMPATHOMIMETICS › Anticholinesterases |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Ambenonium is on its molecule page.
| Molecular formula | C28H42Cl2N4O2 |
|---|---|
| Molecular weight | 537.57 g/mol |
| CAS number | 7648-98-8 |
| InChIKey | OMHBPUNFVFNHJK-UHFFFAOYSA-P |
| PubChem CID | 2131 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Ambenonium used for?
DrugCentral lists the following indications for Ambenonium: Myasthenia gravis.
How does Ambenonium work?
Ambenonium is classified as Cholinesterase Inhibitors; its molecular targets in DrugCentral include ACHE, Ache and ACHE (inhibitor).
When was Ambenonium first approved?
Ambenonium was first approved by the FDA in 1956.
What drug class does Ambenonium belong to?
Ambenonium is in the Cholinesterase Inhibitor class.
What is the chemical formula of Ambenonium?
Ambenonium has the molecular formula C28H42Cl2N4O2 and a molecular weight of 537.57 g/mol.
Browse: all drugs starting with A · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 146 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1200541 — compound record and bioactivity
- PubChem CID 2131 — chemical identifiers
- DrugBank DB01122 — drug record
- FDA UNII L16PUN799N — substance identity
- DailyMed: FDA labels for Ambenonium — current prescribing information (label search)
- UniProt P22303 (ACHE) — target protein
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.